Search
forLearn
5 / 801 resultslearn Metformin
diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties
learn Gluconolactone
learn HYDROXYPROPYLGLUCONAMIDE
learn Glucosyl Rutin
Research
5 / 187 results
research Treatment of Lipodystrophy with Troglitazone
Troglitazone increases subcutaneous fat in lipodystrophy patients.
research Obesity and polycystic ovary syndrome
Obesity increases the risk of developing polycystic ovary syndrome, and weight loss can improve the condition.
research INSULIN-LOWERING MEDICATIONS IN POLYCYSTIC OVARY SYNDROME
Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.
research Use of Insulin-Sensitizing Agents in Patients With Polycystic Ovary Syndrome
Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.
research Insulin Resistance and Polycystic Ovary Syndrome
Insulin resistance is linked to PCOS and can lead to other health issues, but treatments like metformin can help manage symptoms.
Community Join
5 / 1000+ resultscommunity Positive Hair Result in Patient using Tirzepatide
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community What treatment helps diffuse hair thinning from insulin resistance?
The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.